Medicine Prices in Canada: Time for a Change

Maria Puscas co-authored an article examining Canada’s drug pricing framework, focusing on the role of the Patented Medicine Prices Review Board and its proposed guidelines. The article discusses how these changes may affect the availability of new treatments, particularly for rare diseases, and examines the broader implications for clinical trials, market access, and patient access across Canada. (Prior to joining Lenczner Slaght)